SCHEMBL525660

SCHEMBL525660

O=C(O)c1csc(NCc2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
MAPT P10636 6/20 0.54
GAA P10253 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
LMNA P02545 3/20 0.54
RAB9A P51151 2/20 0.54
PKM P14618 1/20 0.54
CHEK1 O14757 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.51
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
MMP13 P45452 1/20 0.51
POLB P06746 1/20 0.51
KDM4E B2RXH2 5/20 0.49
HPGD P15428 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
HTT P42858 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093223 0.87 SCD (0.49) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL525018 0.86 ALDH1A1 (0.60) ALDH1A1MAPTRAB9APKMMMP13
SCHEMBL525241 0.85 NPC1 (0.60) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL6880276 0.82 ROCK2 (0.65) L3MBTL1
SCHEMBL10467196 0.82 SMN1; SMN2 (0.66) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL14268239 0.79 MAPT (0.60) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL7016372 0.79 SCD (0.61) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL525190 0.79 MAPT (0.58) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL8288752 0.77 ALDH1A1 (0.48) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL25083597 0.77 L3MBTL1 (0.62) ALDH1A1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US claimed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO claimed
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US disclosed
US-20120029029-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 US disclosed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029029-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HSD11B1, HSD11B2, HSD3B1 ALDH1A1 196/4885MAPT 2385/4885GAA 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.